Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer. Arlene Siefker-Radtke, MD: Another interesting trial presented at ...

Disitamab vedotin achieved ORR 54.9% (HER2-positive) and 52.6% (HER2-low), with complete responses 16.9% and 18.4%, supporting efficacy beyond strictly HER2-amplified tumors. Clinical benefit was ...

(RTTNews) - Biotechnology company Seagen Inc. (SGEN) and Chinese biopharmaceutical company RemeGen Co., Ltd. on Monday said they have entered into a licensing agreement for RemeGen's disitamab vedotin ...

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as ...

Research published in Frontiers of Medicine evaluates the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of ...

Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): An open-label, single-arm, phase II study. This is an ASCO Meeting ...

RemeGen Co., Ltd ("RemeGen" or "the Company"), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of ...

The median overall survival was 31.5 months in the disitamab vedotin-toripalimab arm and 16.9 months in the chemotherapy arm. First-line treatment with disitamab vedotin and toripalimab can improve ...

The objective response rate was 54.9% in the HER2-positive patients and 52.6% in the HER2-low patients. Disitamab vedotin has shown antitumor activity across HER2-expressing subgroups with pretreated, ...

The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of ...